3Huang PC, Huang CY, Huang SW, et al. High incidence of and risk factors for metachronous bilateral upper tract urotheliat carcinoma in Taiwan. Int J Urol, 2006, 13(7) :864- 869.
4LiaoCH, Chueh SC, Lai MK, et al. Transitional cell carcinoma in renal transplant recipients. Transplant Proc, 2004, 36(7) ..2152-2153.
5Marcen R, Pascual J, Taro AM, et al. Influence of immunosuppression on the prevalence of cancer after kidney transplantation. Transplant Proc, 2003, 35(5)..1714-1716.
6Luan FL, Ding R, Sharma VK. et al. Rapamycin is an effective inhibitor of human renal cancer metastasis . Kidney Int, 2003, 63(3) : 917-926.
7Kahan BD, Knight R. Schoenherg L. et al. Ten years of sirolimus therapy for human renal transplantation: the University of Texas at Houston experience. Transplant Proc, 2003, 35 Suppl 3 : S25-34.
8Campistol JM, Eris J, Oberbauer R , et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation . J Am Soc Nephrol ,2006 , 17 (2) :581-589.
9Kochl GE. Andrassy J. Guba M, et al . Rapamycin protects allografts from rejection while simuhaneously attacking tumors in immunosuppressed mice. Transplantation , 2004 , 77 (9) : 1319- 1326.
10Abraham RT. Wiederrecht GJ. Immunopharmacology of rapamycin. Annu Rev Immunol, 1996, 14 (3) : 483-510.
